现代检验医学杂志2024，Vol.39Issue(3)：152-156,193,6.DOI:10.3969/j.issn.1671-7414.2024.03.026
帕金森病患者血清FGF22和CXCL16水平检测对认知障碍的诊断价值
Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson's Disease for Cognitive Impairment
摘要
Abstract
Objective To explore the diagnostic value of serum levels of fibroblast growth factor 22(FGF22)and CXC chemokine ligand 16(CXCL16)in patients with Parkinson's disease(PD)in cognitive impairment.Methods A total of 125 PD patients admitted to Handan Traditional Chinese Medicine Hospital from June 2022 to June 2023 were selected as the research subjects,and they were separated into a non cognitive impairment group(n=38)and a cognitive impairment group(n=87)based on whether they had cognitive impairment.Enzyme-linked immunosorbent assay(ELISA)was applied to determine the levels of serum FGF22 and CXCL16 in each group.Spearman correlation was applied to analyze the correlation among serum FGF22 and CXCL16 expression levels,Unified Parkinson's Disease Rating Scale(UPDRS)and Montreal Cognitive Assessment(MoCA)scores.Multivariate logistic regression was applied to analyze the factors affecting cognitive impairment in PD patients.Receiver operating characteristic(ROC)curve was applied to analyze the diagnostic efficacy of FGF22 and CXCL16 for cognitive impairment in PD patients.Results Compared with the non cognitive impairment group,the expression level of serum FGF22(184.16±14.62ng/ml vs 203.24±12.15ng/ml)in cognitive impairment group and the MoCA score(23.91±3.14 分 vs 26.54±2.31 分)were decreased(t=7.048,4.460,all P＜0.05),while the expression levels of CXCL16(2.59±0.46ng/ml vs 2.06±0.34ng/ml)and the UPDRS score(41.43±5.62 score vs 32.46±4.28 score)were increased(t=6.376,8.782,all P＜0.05),and the differences were statisaically significant.According to Spearman correlation analysis,the expression level of serum FGF22 was negatively correlated with UPDRS score(r=-0.435,P＜0.05),but positively correlated with MoCA score(r=0.742,P＜0.05).The expression level of CXCL16 in serum was positively correlated with UPDRS score(r=0.532,P＜0.05),but negatively correlated with MoCA score(r=-0.623,P＜0.05).Multivariate logistic analysis showed that FGF22 and MoCA scores were protective factors for cognitive impairment in PD patients(all P＜0.05),while CXCL16 and UPDRS scores were risk factors for cognitive impairment in PD patients(all P＜0.05).The combination of serum FGF22 and CXCL16 in the diagnosis of cognitive impairment in PD patients had better AUC than their respective alone diagnoses(Z=2.919,2.437,P=0.003,0.015),with a sensitivity and a specificity of 93.10％and 73.68％,respectively.Conclusion The levels of serum FGF22 and CXCL16 were closely related to cognitive impairment in PD patients,and the combination of the two could better diagnose whether PD patients have cognitive impairment.关键词
成纤维细胞生长因子22/CXC型趋化因于配体16/帕金森病/认知障碍Key words
fibroblast growth factor 22/CXC chemokine ligand 16/Parkinson's disease/cognitive impairment分类
医药卫生引用本文复制引用
牛荣荣,宋世雄,宋蕾..帕金森病患者血清FGF22和CXCL16水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(3):152-156,193,6.基金项目
河北省中医药管理局科研计划项目(2018393). （2018393）
